One year ago, an iHub survey (#msg-8955911) asked what will be “the most exciting thing about Pfizer during 2006.”
Those who answered with choice c) “Pipeline progress, especially for the HDL-raising drug, Torcetrapib” clearly got it right, but probably not for the reason they expected.
Be careful what you ask for…you may get it
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”